瑞舒伐他汀辅治冠心病介入术后患者的疗效及其对血清IGF-Ⅰ、sE-selectin、TGF-β1水平的影响

Effect of atorvastatin on serum levels of IGF-I,sE-selectin and TGF-β1 in patients with coronary heart disease after PCI and its significance

目的观察瑞舒伐他汀辅治冠心病介入术后患者的疗效及其对血清胰岛素样生长因子-Ⅰ(IGF-Ⅰ)、可溶性E选择素(sE-selectin)、转化生长因子-β1(TGF-β1)的影响。方法选择2014年6月-2015年6月广东医学院附属深圳宝安区中心医院社康科诊治的冠心病介入术后患者120例作为研究对象,根据抽签法随机分为观察组(n=60)及对照组(n=60)。对照组口服硫酸氢氯吡格雷片,观察组在对照组基础上加服瑞舒伐他汀,治疗2个月后比较2组临床治疗效果,治疗前后血脂水平、斑块大小及血清IGF-Ⅰ、sE-selectin、TGF-β1水平。结果观察组总有效率为96.67%,高于对照组的83.34%(X^2=5.926,P=0.015)。观察组血清sE-selectin水平低于对照组[(9.12±1.52)ng/ml vs.(22.78±3.48)ng/ml,t=23.31,P<0.05],而血清IGF-Ⅰ、TGF-β1水平高于对照组[(485.23±42.22)mmol/L vs.(375.25±36.69)mmol/L、(118.96±32.25)pg/ml vs.(85.69±22.52)pg/ml,t=12.743、5.481,P<0.05]。观察组治疗后TG、TC、LDL-C水平低于对照组[(2.06±0.76)mmol/L vs.(2.58±0.74)mmol/L、(4.05±0.62)mmol/L vs.(5.36±0.58)mmol/L、(3.45±0.70)mmol/L vs.(4.22±0.62)mmol/L,t=3.860、12.349、6.484,P<0.05],而HDL-C水平高于对照组[(2.88±0.65)mmol/L vs.(2.32±0.72)mmol/L,t=4.546,P<0.05]。观察组患者治疗后斑块面积、IMT水平低于对照组[(15.25±4.89)mmol/L vs.(22.02±5.66)mmol/L、(0.76±0.22)mm vs.(1.02±0.36)mm,t=7.127、4.852,P<0.05]。结论瑞舒伐他汀能有效调节冠心病介入术后患者血清IGF-Ⅰ、sE-selectin、TGF-β1水平,减轻动脉粥样硬化,提高患者治疗效果。

Objective To explore the effect of rosuvastatin in adjuvant treatment of patients with coronary heart dis -ease after percutaneous coronary intervention on the efficacy and serum insulin -like growth factor 1 （IGF-1）, E selectin （sE-selectin）, transforming growth factor beta 1 （TGF-β1）.Methods One hundred and twenty cases of patients with coronary heart disease according to randomly divided into the observation group （ n =60） and control group （ n =60）, control group was treated with sulfuric acid hydrogen clopidogrel tablets for oral treatment , the observation group in the control group on the basis of and service rosuvastatin treatment with a statin , comparative analysis the clinical therapeutic effect of the two groups , observe the two groups before and after treatment two groups of lipid levels , patch size and serum IGF-I and sE-selectin, TGF-β1 level.Results The total efficiency of the observation group was 96.67%, higher than 83.34%in the control group （χ2 =5.926, P 〈0.05）.The observation group serum sE-selectin levels than the control group [ （9.12 ±1.52） ng/ml vs.（22.78 ± 3.48）ng/ml, t =23.31, P 〈0.05], serum IGF-I, and TGF-β1 were higher than the control group[（485.23 ±42.220 mmol/L vs.（375.25 ±36.69） mmol/L, （118.96 ±32.25） pg/ml vs.（85.69 ±22.52） pg/ml, t =12.743, t =5.481, P 〈0.05].TG, TC and LDL-C levels after treatment in the observation group were lower than the control group [（2.06 ±0.76） mmol/L vs.（2.58 ±0.74）, mmol/L, （4.05 ±0.62） mmol/L vs.（5.36 ±0.58） mmol/L, （3.45 ±0.70） mmol/L vs. （4.22 ±0.62） mmol/L, t =3.860, t =12.349, t =6.484, P 〈0.05].HDL-C was higher than the control group [（2.88 ±0.65） mmol/L vs.（2.32 ±0.72） mmol/L, t =4.546, P 〈0.05].The area of plaque and IMT level in the ob-servation group were lower than that in the control group [（15.25 ±4.89） mmol/L vs.（5.66 ±22.02） mmol/L, （0.76 ± 0.22） mm vs.（0.36 ±1.02） mm, t =7.127, t =4.852, P 〈0.05].Conclusion Atorvastatin can effectively regulate the level of serum IGF-I, sE-selectin TGF-β1 in patients with coronary heart disease after PCI , reduce atherosclerosis , improve the treatment effect of patients .